TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Thursday, 19th December at 9:15 am
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration
Collaboration partner to use AI and machine learning to identify targeted patient pool
Potential entry into high growth GLP-1 market valued at nearly $50 billion in 2024 and projected to surpass $100 billion by 2029
TNF Pharmaceuticals, Inc. (NASDAQ: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug isomyosamine (MYMD-1) as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate TNF-α levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia.
"The GLP-1 drug class has transformed the pharmaceutical landscape in recent years as the prevalence of obesity surges to record numbers. While GLP-1 receptor agonists are highly effective in treating overweight and obesity, rapid and extensive weight loss can bring a range of dangerous complications including sarcopenic loss of muscle mass and bone density," said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. "Since our lead drug targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia, we believe it could provide a much-needed solution for preserving muscle mass in GLP-1-induced weight loss.
Thursday, 19th December at 9:15 am
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration
Collaboration partner to use AI and machine learning to identify targeted patient pool
Potential entry into high growth GLP-1 market valued at nearly $50 billion in 2024 and projected to surpass $100 billion by 2029
TNF Pharmaceuticals, Inc. (NASDAQ: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug isomyosamine (MYMD-1) as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate TNF-α levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia.
"The GLP-1 drug class has transformed the pharmaceutical landscape in recent years as the prevalence of obesity surges to record numbers. While GLP-1 receptor agonists are highly effective in treating overweight and obesity, rapid and extensive weight loss can bring a range of dangerous complications including sarcopenic loss of muscle mass and bone density," said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. "Since our lead drug targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia, we believe it could provide a much-needed solution for preserving muscle mass in GLP-1-induced weight loss.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment